Major participants in the cystic fibrosis therapeutics industry comprise AbbVie Inc., Allergan Plc, Chiesi Farmaceutici S.p.A., F. Hoffmann-La Roche AG, Gilead Sciences, Inc., Novartis International AG, Pharmaxis Ltd., PTC Therapeutics, and Vertex Pharmaceuticals, Inc.
The increasing number of patients with cystic fibrosis, high prevalence in the pediatric and adult population, and increasing research & development spending are dynamically shaping the global cystic fibrosis therapeutics market.
North America contributed the largest share to the global cystic fibrosis therapeutics market and is anticipated to be the dominating geography throughout the forecast period.
Based on drug class, the cystic fibrosis therapeutics market is segmented into pancreatic enzyme supplements, mucolytics, bronchodilators, and CFTR modulators.
The cystic fibrosis therapeutics market was valued at US$ 5.6 billion in 2021.
The cystic fibrosis therapeutics market is anticipated to expand at a CAGR of 15% from 2023 to 2032.
Copyright © 2024 Same Page Management Consulting Pvt. Ltd. (insightSLICE) | All Rights Reserved